Merck Sharp + Dohme Corp.

Bausch & Lomb Incorporated

Brent Whitehead

Amjad Ali

Michael Man-Chu Lo

Michael Hall

Hongna Wang

Stephen R Davio

Gregory L McIntire

Shazad Suchit

Jon Summersett

Timothy J Henderson

Jerry Andrew Taylor

Brian Alexander McKittrick

Sung-Sau So

Shrenik K Shah

Zhicai Wu

Lin Yan

Robert K Baker

Peter Orth

Jacqueline D Hicks

Christopher L Franklin

Edward Metzger

Zhiqiang Guo

Hong Dong Chu

Matthew Lombardo

Andrew William Stamford

Kathleen M Rupprecht

Yusheng Xiong

John S Debenham

Rongze Kuang

Ashwin Umesh Rao

Yeon-Hee Lim

Manuel De Lera Ruiz

Clare London

Paul Tempest

Andrew John Cooke

Min K Park

Scott B Hoyt

John K MacLean

Heping Wu

Emma Louise Carswell

Ping Lan

Sathesh P Bhat

Paul David Ratcliffe

Markus Kristofer Dahlgren

D Jonathan Bennett

Zhongxiang Sun

Gioconda V Gallo

Jun Wang

Revathi Reddy Katipally

Jaiqiang Cai

Xiaoqing Han

James Dellureficio

Ali Amjad

Michael Lo

Amy Bittner McCracken

Jonathan E Gable

The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of Areceptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which Areceptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which Areceptors are involved.

2,2-difluorodioxolo Areceptor antagonists

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

This invention relates to imidazopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Imidazopyridyl compounds as aldosterone synthase inhibitors

A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. 

Diazeniumdiolate heterocyclic derivatives

A polymorph of brimonidine pamoate having the formula exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Polymorphs of brimonidine pamoate

A compound having the structure wherein Y is selected from the group consisting of &#x2014;C(O)OR, &#x2014;C(O)NHR, &#x2014;C(CH)OR3, OH, and or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. 

Nitrooxy cycloalkane derivatives

A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formula  The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

Primary amine diazeniumdiolate heterocyclic derivatives

A compound having the structure wherein R is an angiotensin receptor antagonist active group, and&#x2014;C(RH)OC(O)X((CRR)&#x2014;(CHR)&#x2014;(CH)&#x2014;Z&#x2014;(CH)&#x2014;(CHR)&#x2014;(CRR))&#x2014;R;&#x2003;&#x2003;2)

Angiotensin II receptor antagonists

A brimonidine (5-bromo-6-(2-imidazolidinylideneamino)quinoxaline) pamoate polymorph exhibits characteristics disclosed herein. The brimonidine pamoate polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

Growing community of inventors

Piscataway, NJ, United States of America

Brent Whitehead